Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry

被引:207
作者
Hopkin, Robert J. [1 ,3 ]
Bissler, John [2 ,3 ]
Banikazemi, Maryam [4 ,5 ]
Clarke, Lorne [6 ]
Eng, Christine M. [7 ]
Germain, Dominique P. [8 ]
Lemay, Roberta [9 ]
Tylki-Szymanska, Anna [10 ]
Wilcox, William R. [11 ,12 ]
机构
[1] Cincinnati Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp, Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA
[3] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA
[4] NYU, Dept Neurol, New York, NY 10016 USA
[5] NYU, Dept Pediat, New York, NY 10016 USA
[6] Univ British Columbia, Dept Med Genet, Vancouver, BC V6H 3N1, Canada
[7] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[8] Univ Versailles, Hop Raymond Poincare, AP HP, F-92380 St Quentin en Yvelines, Garches, France
[9] Genzyme Corp, Biomed Operat, Cambridge, MA 02142 USA
[10] Klin Chorob Metabol, Dept Pediat, PL-04736 Warsaw, Poland
[11] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA
[12] Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA
关键词
D O I
10.1203/PDR.0b013e318183f132
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Fabry disease is an X-linked lysosomal disease caused by deficiency of alpha-galactosidase A. Signs and symptoms of Fabry disease occurring during, childhood and adolescence were characterized in 352 Fabry Registry patients. At enrollment (median age 12 year), 77% of males and 51% of females reported symptoms. The median age of symptom onset was 6 year in males and 9 year in females. The most frequent symptom, neuropathic pain, was reported by 59% of males (median age 7 year) and 41% of females (median age 9 year). Gastrointestinal symptoms were reported by 18% of children (median age 5 year in males and 9.5 year in females). Males exhibited height and weight values below the US 50th percentile. Females had weight values above the US 50th percentile, A few patients had serious renal and cardiac manifestations, stage 2 or 3 chronic kidney disease (n = 3), arrhythmia (n = 9), and left ventricular hypertrophy (n = 3). Thus, many pediatric Fabry patients report early symptoms, particularly pain. gastrointestinal symptoms, and impaired quality of life. Some children experience major complications during the pediatric years. (Pediatr Res 64: 550-555, 2008)
引用
收藏
页码:550 / 555
页数:6
相关论文
共 22 条
[21]   Long-term safety and efficacy of enzyme replacement therapy for Fabry disease [J].
Wilcox, WR ;
Banikazemi, M ;
Guffon, N ;
Waldek, S ;
Lee, P ;
Linthorst, GE ;
Desnick, RJ ;
Germain, DP .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (01) :65-74
[22]   Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease [J].
Wraith, J. Edmond ;
Tylki-Szymanska, Anna ;
Guffon, Nathalie ;
Lien, Y. Howard ;
Tsimaratos, Michel ;
Vellodi, Ashok ;
German, Dominique P. .
JOURNAL OF PEDIATRICS, 2008, 152 (04) :563-570